BMI-1 Autoantibody as a New Potential Biomarker for Cervical Carcinoma
Open Access
- 21 November 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11), e27804
- https://doi.org/10.1371/journal.pone.0027804
Abstract
BMI-1 is overexpressed in a variety of cancers, which can elicit an immune response leading to the induction of autoantibodies. However, BMI-1 autoantibody as a biomarker has seldom been studied with the exception of nasopharyngeal carcinoma. Whether BMI-1 autoantibodies can be used as a biomarker for cervical carcinoma is unclear. In this study,BMI-1 proteins were isolated by screening of a T7 phage cDNA library from mixed cervical carcinoma tissues. We analyzed BMI-1 autoantibody levels in serum samples from 67 patients with cervical carcinoma and 65 controls using ELISA and immunoblot. BMI-1 mRNA or protein levels were over-expressed in cervical carcinoma cell lines. Immunoblot results exhibited increased BMI-1 autoantibody levels in patient sera compared to normal sera. Additionally, the results for antibody affinity assay showed that there was no difference between cervical polyps and normal sera of BMI-1 autoantibody levels, but it was significantly greater in patient sera than that in normal controls (patient 0.827±0.043 and normal 0.445±0.023; PPP<0.001). Statistical analyses using logistic regression and receiver operating characteristics (ROC) curves indicated that the BMI-1 autoantibody level can be used as a biomarker for cervical carcinoma (sensitivity 0.78 and specificity 0.76; AUC = 0.922). In conclusion, measuring BMI-1 autoantibody levels of patients with cervical cancer could have clinical prognostic value as well as a non-tissue specific biomarker for neoplasms expressing BMI-1.This publication has 35 references indexed in Scilit:
- Expression of BMI-1 and Mel-18 in breast tissue - a diagnostic marker in patients with breast cancerBMC Cancer, 2010
- Polycomb Target Genes Are Silenced in Multiple MyelomaPLOS ONE, 2010
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural ChinaThe Lancet Oncology, 2008
- Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trialThe Lancet Oncology, 2008
- Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing CountriesVaccine, 2008
- Autoantibodies as potential biomarkers for nasopharyngeal carcinomaProteomics, 2008
- Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigensBritish Journal of Cancer, 2006